Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

At the meeting, GlaxoSmithKline (GSK) of Rixensart, Belgium,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
RNsidersbuying Member Profile
 
Followed By 34
Posts 3,047
Boards Moderated 1
Alias Born 07/26/10
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 5:28:29 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 5:08:57 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 2:08:05 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 10:30:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 8:12:12 AM
GlaxoSmithKline: Phase 3 Study of Zejula Met Trial Objectives Dow Jones News - 7/15/2019 2:43:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/12/2019 1:13:34 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/12/2019 1:04:43 PM
EU Approves With Conditions GlaxoSmithKline's Acquisition of Pfizer's Consumer Health Business Dow Jones News - 7/11/2019 5:02:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2019 12:00:33 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2019 6:17:08 AM
GlaxoSmithKline, Pfizer's HIV Treatment Meets Primary Endpoint in Trial Dow Jones News - 7/10/2019 2:54:00 AM
Fulcrum Therapeutics Sets IPO at 4.5 Million Shares; Sees Pricing at $16-$18 Apiece Dow Jones News - 7/8/2019 7:13:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/3/2019 7:59:46 AM
South Africa Gives Conditional Go-Ahead to GSK-Pfizer JV -Reuters Dow Jones News - 7/2/2019 2:10:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2019 10:46:28 AM
Liquidia Technologies Gets Right to Develop More Products in Revised GlaxoSmithKline Agreement Dow Jones News - 6/26/2019 7:28:00 PM
GSK Offers Concessions on Pfizer JV to Quell EU Antitrust Fears Dow Jones News - 6/20/2019 6:53:00 AM
Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece Dow Jones News - 6/14/2019 8:04:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2019 1:32:53 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/7/2019 6:38:58 AM
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options Business Wire - 6/6/2019 5:15:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 6:22:29 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/3/2019 11:12:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 2:05:17 PM
RNsidersbuying   Thursday, 10/23/14 05:22:00 PM
Re: None
Post # of 137 
At the meeting, GlaxoSmithKline (GSK) of Rixensart, Belgium, which has the vaccine furthest in development, spelled out how it might scale up production in parallel with the safety and efficacy trials now under way so that the product could be ready for wider distribution by April if warranted. The company expects to have preliminary data in November from phase I studies that analyze safety and immune response in small numbers of people not at risk of contracting Ebola. If those data are positive, efficacy trials could start as early as January in Guinea, Sierra Leone, and Liberia, the three West African countries hard hit by the epidemic.

GSK estimates (see table below, and here) that it will have 24,000 doses of its vaccine ready by January for the efficacy trials. If it cranks up production to full capacity before the those trials are complete, the company could have 230,000 doses available in April, and then could steadily increase capacity to produce more than 1 million doses a month by December 2015.


http://news.sciencemag.org/health/2014/10/leaked-documents-reveal-behind-scenes-ebola-vaccine-issues



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist